NCT02742987

Clopidogrel Versus Ticagrelor in Type-2 Diabetes

CLOpidogrel Versus TIcagreLor for Antiplatelet Maintenance in DIAbetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Campus Bio-Medico University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and platelet reactivity in patients with type-2 diabetes mellitus (T2DM) treated with percutaneous coronary intervention (PCI).

Conditions

• Coronary Artery Disease
• Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Ticagrelor	Ticagrelor 90 mg twice daily
DRUG	Clopidogrel	Clopidogrel 150 mg once daily
DRUG	Standard medical therapy	Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions

Timeline

• Start date: 2014-03-01
• Primary completion: 2015-06-01
• Completion: 2015-06-01
• First posted: 2016-04-19
• Last updated: 2017-08-17
• Results posted: 2017-08-17